Opens in a new tab or window The FDA on Tuesday approved mirdametinib (Gomekli) for adults and kids ages 2 and up with neurofibromatosis ... including retinal vein occlusion, retinal pigment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback